Related Experiment Videos
Protein kinase C inhibitors
Helen C Swannie1, Stanley B Kaye
1CRC Department of Medical Oncology, Royal Marsden Hospital, Sutton, Surrey, UK SM2 5NG. hswannie@icr.ac.uk
Abstract:
Protein kinase C (PKC) is a family of serine-threonine protein kinases that are involved in signal transduction pathways that regulate growth factor response, proliferation, and apoptosis. Its central role in these processes, which are closely involved in tumor initiation, progression, and response to antitumor agents, makes it an attractive therapeutic target in cancer. Despite initial activity seen in melanoma (bryostatin and UCN-01), non-Hodgkin's lymphoma (ISIS 3521, bryostatin, and UCN-01), and ovarian carcinoma (ISIS 3521 and bryostatin) in phase I studies, single-agent activity in those phase II studies reported to date has been limited. Preclinical data highlight a role for PKC in modulation of drug resistance and synergy with conventional cytotoxic drugs. A randomized phase III study of ISIS 3521 in combination with carboplatin and paclitaxel, compared with chemotherapy alone, in advanced non-small-cell lung cancer is underway. This paper reviews the rationale for using PKC inhibitors in cancer therapy, the challenges for clinical trial design, and the recent clinical experience with modulators of PKC activity.
Insights
Protein kinase C (PKC) inhibitors show promise in cancer therapy by targeting key cell processes. While single-agent activity is limited, preclinical data suggest synergy with conventional drugs, warranting further clinical investigation.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Protein kinase C (PKC) is a key regulator of cell signaling pathways implicated in cancer initiation and progression.
- PKC's role in tumor growth and drug resistance makes it a significant therapeutic target in oncology.
- Modulators of PKC activity are being investigated for their potential in cancer treatment.
Purpose of the Study:
- To review the rationale for utilizing PKC inhibitors in cancer therapy.
- To discuss the challenges associated with designing clinical trials for PKC inhibitors.
- To summarize recent clinical experiences with PKC activity modulators.
Main Methods:
- Review of preclinical data on PKC's role in cancer and drug resistance.
- Analysis of clinical trial results for PKC inhibitors in various cancer types.
- Discussion of ongoing and future clinical studies involving PKC modulators.
Main Results:
- PKC plays a central role in cancer-related signaling pathways, including proliferation and apoptosis.
- Limited single-agent activity of PKC inhibitors has been observed in phase II clinical trials.
- Preclinical studies indicate that PKC inhibition can modulate drug resistance and enhance the efficacy of cytotoxic agents.
Conclusions:
- PKC inhibitors represent a promising therapeutic strategy in oncology, particularly in combination regimens.
- Further research and optimized clinical trial designs are necessary to fully realize the potential of PKC inhibitors.
- Ongoing phase III trials are evaluating the efficacy of PKC inhibitors in combination with standard chemotherapy for advanced cancers.